Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745168 | 0.81 | GAA (0.32) | GAA | |
| SCHEMBL28061551 | 0.77 | — | — | |
| SCHEMBL1549646 | 0.75 | DGAT1 (0.38) | — | |
| SCHEMBL331834 | 0.71 | — | — | |
| SCHEMBL11163157 | 0.71 | KEAP1 (0.33) | — | |
| SCHEMBL4104284 | 0.70 | — | — | |
| SCHEMBL29119800 | 0.69 | — | — | |
| SCHEMBL1687808 | 0.69 | — | — | |
| Water SCHEMBL30726534 | 0.69 | — | — | |
| SCHEMBL16761002 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101563084-B | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICALS LTD | 2013-02-20 | — | — | CN | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2378879-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2035381-B1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| CN-101563084-A | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | CN | disclosed |
| EP-2035381-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | Ciba Holding Inc. (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008109104-A1 | BIVALENT INHIBITORS OF AKT PROTEIN KINASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008003602-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | CIBA HOLDING INC. (CH) | 2008-01-10 | — | — | WO | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-6416905-B1 | 1 TO 95% BY WEIGHT OF A SOLID, HAVING A PRIMARY PARTICLE SIZE OF 5 NM TO 20 MICRONS, AND A POLYMER; ELECTROLYTIC CELL | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-09 | — | — | US | disclosed |
| EP-0996606-B1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 CHEMICALS LTD (GB) | 2002-01-16 | — | — | EP | disclosed |
| US-6300511-B1 | FLUORINATING CARBONYL COMPOUND BY REPLACEMENT OF ALPHA-HYDROGEN ATOM WITH FLUORINE COMPRISING REACTING COMPOUND WITH FLUORINATING AGENT IN PRESENCE OF CATALYTICALLY EFFECTIVE AMOUNT OF TRANSITION METAL-CONTAINING CATALYST | F2 CHEMICALS LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| US-6255518-B1 | Preparation of fluorinated compounds | F2 CHEMICALS, LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| EP-1001918-A1 | PREPARATION OF FLUORINATED COMPOUNDS | F2 Chemicals Limited (GB) | 2000-05-24 | — | — | EP | disclosed |
| EP-0996606-A1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 Chemicals Ltd. (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999005080-A1 | PREPARATION OF FLUORINATED COMPOUNDS | F2 CHEMICALS LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999003802-A1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 CHEMICALS LIMITED (GB) | 1999-01-28 | — | — | WO | disclosed |
| EP-0696272-A1 | CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITING N(3-BIPHENYLYL-1(S)-METHYL-2-PROPENYL) ACETOHYDROXAMIC ACID DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025431-A1 | CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITING N(3-BIPHENYLYL-1(S)-METHYL-2-PROPENYL) ACETOHYDROXAMIC ACID DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | GAA 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.